Darzalex (daratumumab) Injection For Sale

Brand name - Darzalex 

Generic name - Daratumumab 

Type - Whole antibody 

Manufacturer - Janssen Biotech, Inc. 

Composition - 20 mg Daratumumab per mL 

Storage - Store Darzalex in a refrigerator at 2°C to 8°C (36°F to 46°F). 

Dosage form - Injection 

Strength - 100mg/5mL 

Packaging - Single dose vial 

Indication - Used in the treatment of multiple myeloma in adults 

Description 

Daratumumab is an anticancer drug. It is used in the treatment of multiple myeloma. Multiple myeloma is a type of cancer that affects white blood cells, also known as plasma cells. Darzalex is a monoclonal antibody, which is directed against CD38, a molecule present on myeloma cells. It's believed that Darzalex induces tumor cell death through multiple immune-mediated mechanisms of action,8,9 in addition to apoptosis, in which a series of molecular steps in a cell lead to its death. 

Ingredients Of Darzalex 

The active ingredient of Darzalex is Daratumumab. 

Pharmacodynamics Of Darzalex

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. 

Mechanism Of Action 

Daratumumab is an IgG1κ human monoclonal antibody (mAb) that binds to the CD38 protein expressed at a high level on the surface of multiple myeloma tumor cells, as well as other cell types and tissues at various levels. CD38 protein has multiple functions such as receptor-mediated adhesion, signaling and enzymatic activity. 

Daratumumab has been shown to potently inhibit the in vivo growth of CD38-expressing tumor cells. Based on in vitro studies, daratumumab may utilize multiple effector functions, resulting in immune-mediated tumor cell death. These studies suggest that daratumumab can induce tumor cell lysis through complement-dependent cytotoxicity, antibody-dependent cell-mediated cytotoxicity, and antibody-dependent cellular phagocytosis in malignancies expressing CD38. A subset of myeloid-derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs), and B cells (CD38+Bregs) are decreased by daratumumab mediated cell lysis. T cells (CD3+, CD4+, and CD8+) are also known to express CD38 depending on the stage of development and the level of activation. Significant increases in CD4+ and CD8+ T cell absolute counts, and percentages of lymphocytes, were observed with daratumumab treatment in peripheral whole blood and bone marrow. In addition, T-cell receptor DNA sequencing verified that T-cell clonality was increased with daratumumab treatment, indicating immune-modulatory effects that may contribute to clinical response. 

Daratumumab induced apoptosis in vitro after Fc mediated cross-linking. In addition, daratumumab modulated CD38 enzymatic activity, inhibiting the cyclase enzyme activity and stimulating the hydrolase activity. The significance of these in vitro effects in a clinical setting, and the implications on tumour growth, are not well-understood. 

Pharmacodynamic Effects Of Darzalex

Natural killer (NK) cell and T-cell count. 

NK cells are known to express high levels of CD38 and are susceptible to daratumumab mediated cell lysis. Decreases in absolute counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56dim) NK cells in peripheral whole blood and bone marrow were observed with daratumumab treatment. However, baseline levels of NK cells did not show an association with clinical response.  

Usage Of Medicine Of Darzalex

Darzalex is used in the treatment of multiple myeloma, which is a type of cancer.